Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Rizzo

Showing results (31-40 of 381) with videos related to

Pageof 39
Sort By:
Cancer Treatment and Research Communications|March 22, 2021
TRK inhibition in cholangiocarcinoma: Trying to teach an old dog new tricksAlessandro Rizzo, Giovanni Brandi
Cancer Treatment and Research Communications|February 16, 2021
First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: "And Yet It Moves!"Alessandro Rizzo, Giovanni Brandi
International Journal of Molecular Sciences|September 23, 2022
IDH Inhibitors and Immunotherapy for Biliary Tract Cancer: A Marriage of Convenience?Giovanni Brandi, Alessandro Rizzo
Expert Review of Gastroenterology & Hepatology|August 23, 2022
Bayesian analysis and the role of local palliative therapeutics for malignant biliary obstructionAlessandro Rizzo, Giovanni Brandi
Medicina (Kaunas, Lithuania)|December 24, 2021
Dual HER2 Blockade: An Emerging Option in Metastatic Biliary Tract Cancer?Angela Dalia Ricci, Alessandro Rizzo
Expert Opinion on Investigational Drugs|August 25, 2021
PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?Alessandro Rizzo, Angela Dalia Ricci
International Journal of Molecular Sciences|October 14, 2022
Challenges and Future Trends of Hepatocellular Carcinoma ImmunotherapyAlessandro Rizzo, Angela Dalia Ricci
Expert Opinion on Investigational Drugs|November 18, 2021
Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyondAlessandro Rizzo, Angela Dalia Ricci
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2026
Unlocking New Possibilities: Dual Immune Blockade in Brain Metastases from Rare TumorsAngela Dalia Ricci, Alessandro Rizzo
Expert Opinion on Investigational Drugs|February 27, 2025
Unlocking the mechanisms underlying the activity of pembrolizumab plus enfortumab vedotin in patients with urothelial carcinomaMatteo Santoni, Alessandro Rizzo, Francesco Massari
Pageof 39

Showing results (31-40 of 381) with videos related to

Sort By:
Pageof 39
Cancer Treatment and Research Communications|March 22, 2021
TRK inhibition in cholangiocarcinoma: Trying to teach an old dog new tricksAlessandro Rizzo, Giovanni Brandi
Cancer Treatment and Research Communications|February 16, 2021
First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: "And Yet It Moves!"Alessandro Rizzo, Giovanni Brandi
International Journal of Molecular Sciences|September 23, 2022
IDH Inhibitors and Immunotherapy for Biliary Tract Cancer: A Marriage of Convenience?Giovanni Brandi, Alessandro Rizzo
Expert Review of Gastroenterology & Hepatology|August 23, 2022
Bayesian analysis and the role of local palliative therapeutics for malignant biliary obstructionAlessandro Rizzo, Giovanni Brandi
Medicina (Kaunas, Lithuania)|December 24, 2021
Dual HER2 Blockade: An Emerging Option in Metastatic Biliary Tract Cancer?Angela Dalia Ricci, Alessandro Rizzo
Expert Opinion on Investigational Drugs|August 25, 2021
PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?Alessandro Rizzo, Angela Dalia Ricci
International Journal of Molecular Sciences|October 14, 2022
Challenges and Future Trends of Hepatocellular Carcinoma ImmunotherapyAlessandro Rizzo, Angela Dalia Ricci
Expert Opinion on Investigational Drugs|November 18, 2021
Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyondAlessandro Rizzo, Angela Dalia Ricci
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2026
Unlocking New Possibilities: Dual Immune Blockade in Brain Metastases from Rare TumorsAngela Dalia Ricci, Alessandro Rizzo
Expert Opinion on Investigational Drugs|February 27, 2025
Unlocking the mechanisms underlying the activity of pembrolizumab plus enfortumab vedotin in patients with urothelial carcinomaMatteo Santoni, Alessandro Rizzo, Francesco Massari
Pageof 39